Search results for "eps"

showing 10 items of 1777 documents

Mitochondrial transcriptional study of the effect of aflatoxins, enniatins and carotenoids in vitro in a blood brain barrier model

2020

C. maxima (var. Delica), a variety of pumpkin, is well known for its high concentration on carotenoids, possessing dietary benefits and antioxidant properties. Aflatoxins and enniatins are common mycotoxins present in food and feed with an extended toxicity profile in humans and animals. Both types of substances reach a wide range of tissues and organs and have the capability to penetrate the blood brain barrier. Since carotenoids and mycotoxins have been reported to modify diverse mitochondrial processes individually, transcriptional in vitro studies on human epithelial cells ECV 304 were conducted to analyze the relative expression of 13 mitochondria related genes. ECV 304 cells were diff…

AflatoxinMitochondrial DNAAntioxidantmedicine.medical_treatmentAlzheimer Antioxidants Mycotoxicity Neurodegenerative diseases Carotenoids qPCR ECV 304MitochondrionToxicologyBlood–brain barrierAntioxidantsCell LineNOchemistry.chemical_compoundAflatoxinsCucurbitaDepsipeptidesHuman Umbilical Vein Endothelial CellsmedicineHumansECV 304MycotoxinMycotoxicityCarotenoidchemistry.chemical_classificationLS9_6Neurodegenerative diseasesfood and beveragesGeneral MedicineCarotenoidsIn vitroMitochondriaqPCRmedicine.anatomical_structureElectron Transport Chain Complex ProteinschemistryBiochemistryBlood-Brain BarrierAlzheimerFood Science
researchProduct

Epilepsy in the Elderly

2009

Epilepsy is the third most common disease affecting the brain in the elderly. Current demographic trends will lead to an increased prevalence of epilepsy in the general population.A selective literature search revealed 102 relevant publications as of September 2008, 50 of which were original articles.The level of evidence was found to be very low. No guidelines, systematic reviews or meta-analyses are available, and there have been only three randomized, double-blind trials of treatment for epilepsy in the elderly. The seizures often escape clinical attention, because premonitory symptoms (aura) and secondary generalization into tonic-clonic seizures are both rarer in older patients. On the…

Aged 80 and overGeriatricsmedicine.medical_specialtyEpilepsyStatement (logic)business.industryConflict of interestDiagnostic testGeriatric assessmentReview ArticleGeneral Medicinemedicine.diseaseEpilepsymedicineHumansAnticonvulsantsPsychiatrybusinessGeriatric AssessmentAgedDeutsches Ärzteblatt international
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Neural Activation During Submaximal Contractions Seems More Reflective of Neuromuscular Ageing than Maximal Voluntary Activation

2016

International audience; This study aimed at testing the hypothesis that differences in neural activation strategy during submaximal but not maximal plantarflexions exist between young and older men. Eleven young men (YM, 26 +/- 4 years) and thirteen old men (OM, 76 +/- 3 years) volunteered for the investigation. Maximal voluntary torque (MVT) was 38.2%, lower (p < 0.001) in OM than in YM, while voluntary activation was equivalent (similar to 97%). The relationship between the interpolated twitch torque and the voluntary torque (IT-VT relationship) was composite (curvilinear + exponential) for both age-groups. However, the OM showed accentuated concavity, as attested by the occurrence of the…

AgingContraction (grammar)Voluntary activationAgeing.torquein-vivoPlantar flexionActivation patternh-reflex0302 clinical medicineVoluntary contractionmotor unitaging; clinical article; female; human; male; muscle contractility; muscle twitch; nervous system; torque; Ageing; Triceps surae; Twitch interpolation; Voluntary activation; Voluntary contractionTwitch interpolationolder-adultsmuscle contractilityOriginal Researchclinical articlenervous systemmuscle twitchfemalecross-sectional areaCardiologyTriceps suraeforcemedicine.medical_specialtymechanical-propertiesCognitive Neurosciencelcsh:RC321-57103 medical and health sciencesmaleInternal medicinemedicinehumanlcsh:Neurosciences. Biological psychiatry. Neuropsychiatryskeletal-muscle fibersbusiness.industryTwitch interpolation030229 sport sciencesAgeingageAgeingTurnover[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]interpolated twitchPhysical therapybusinessVoluntary contraction030217 neurology & neurosurgeryNeuroscienceFrontiers in Aging Neuroscience
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Velocity-specific training in elbow flexors.

1999

The purpose of this study was to show that velocity-specific training may be implicated in modifications in the level of coactivation of agonist and antagonist muscles. Healthy males (n = 20) were randomly placed in to two groups: one group trained using concentric contractions (n = 12), the other was an untrained control group (n = 8). The training group underwent unilateral resistance training at a level of 35 (5)% of a one-repetition maximal contraction of the elbow flexors, executed at maximal angular velocity. Training sessions consisted of six sets of eight consecutive elbow flexions, three times per weak for a total of seven weeks. The velocity of the ballistic movements executed dur…

AgonistAdultMaleWeight LiftingPhysiologymedicine.drug_classElbowIsometric exerciseConcentricBicepsIsometric ContractionmedicineElbowEccentricHumansMuscle Skeletalbusiness.industryElectromyographyPublic Health Environmental and Occupational HealthAnatomyCoactivationBiomechanical Phenomenamedicine.anatomical_structureTorquePhysical Fitnessmedicine.symptomNuclear medicinebusinessMuscle contractionMuscle ContractionEuropean journal of applied physiology and occupational physiology
researchProduct

Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.

2014

This study aimed at providing an insight on the possible role of cannabi-noid (CB) type 2 receptors (CB2R) and cGMP pathway in the antiepileptic activity ofWIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone, a non-selective CB agonist, in the maximal dentate activation (MDA) model of partial epilepsy in adult male rats. We evaluated the activity of a CB2 antagonist/inverse agonist AM630, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone or 6-iodopravadoline, alone or in co-administration with WIN 55,212-2. Also, in the MDA model it was investigated the co-treatment of WIN55,212…

AgonistMaleIndolessGCmedicine.drug_classmedicine.medical_treatmentMorpholinesPharmacologyNaphthalenesSettore BIO/09 - FisiologiaHippocampusNitric oxideReceptor Cannabinoid CB2chemistry.chemical_compoundHippocampumedicineCannabinoid receptor type 2Inverse agonistAnimalsRats WistarReceptorCannabinoidCannabinoid Receptor AntagonistsCyclic GMPCannabinoid Receptor AgonistsElectrophysiology.ChemistryAntagonistElectric StimulationBenzoxazinesDisease Models AnimalNeurologyGuanylate CyclaseAnticonvulsantsNeurology (clinical)CannabinoidEpilepsies PartialSoluble guanylyl cyclaseTemporal Lobe Epilepsy AM630Epilepsy research
researchProduct

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

2020

Abstract Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimo…

AgonistSphingosine 1 Phosphate Receptor ModulatorsMultiple Sclerosismedicine.drug_classDrug Evaluation PreclinicalDiseaseReview ArticleRM1-950PharmacologyNeuroprotection03 medical and health sciencesEpilepsyMice0302 clinical medicineNeurotrophic factorsAlzheimer DiseasemedicineAnimalsHumansLymphocytes030304 developmental biologyPharmacology0303 health sciencesEpilepsyMicrogliabusiness.industryFingolimod HydrochlorideMultiple sclerosisAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseFingolimod3. Good healthRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsTherapeutics. PharmacologyNervous System Diseasesbusiness030217 neurology & neurosurgerymedicine.drugDrugs in R&D
researchProduct

Akūtas nieru mazspējas analīze Latvijas slimnīcu intensīvās terapijas nodaļās: etioloģisko faktoru, incidences un iznākumu analīze

2015

Tēmas aktualitāte: Akūtas nieru mazspējas (ANM) incidence ar katru gadu pieaug. Tajā pašā laikā ANM diagnostika ir apgrūtināta un tikai neilgu laiku ir pieejamas klīniskās klasifikācijas, kas ļautu savlaicīgi atklāt akūtu nieru slimību. Ņemot vērā to, ka pieaug gan pacientu morbiditāte, gan uzlabojas diagnostika, pieaug arī akūtas nieru slimības incidence intensīvās terapijas nodaļā. Savukārt, lai uzlabotu pacientu prognozi, savlaicīgi veiktu nepieciešamos izmeklējumus un noteiktu nieru bojājumu pirms neatgriezenisku izmaiņu iestāšanās, ir nepieciešams izprast galvenos riska faktorus; jo tikai savlaicīgi diagnosticējot ir iespējams sniegt pilnvērtīgu palīdzību un uzlabot pacienta prognozi. …

Akūta nieru slimībaAkūts nieru bojājumsSepseAkūta nieru mazspējaMedicīnaKontratvielu izraisīta akūta tubulāra nekroze
researchProduct